Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) have been assigned an average rating of “Buy” from the five ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $10.3333.

A number of analysts have commented on the company. HC Wainwright reiterated a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday, July 1st. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a research note on Friday, July 17th. Freedom Capital raised Niagen Bioscience to a “strong-buy” rating in a research report on Monday, July 6th. Finally, Roth Capital reiterated a “buy” rating on shares of Niagen Bioscience in a research note on Wednesday, August 5th.

Institutional Investors Weigh In On Niagen Bioscience

Several institutional investors and hedge funds have recently made changes to their positions in the company. Tieton Capital Management LLC bought a new stake in shares of Niagen Bioscience during the second quarter worth $6,407,000. Bank of New York Mellon Corp bought a new stake in Niagen Bioscience during the 2nd quarter worth about $647,000. Stoneridge Investment Partners LLC bought a new stake in Niagen Bioscience during the 2nd quarter worth about $49,000. Bank of America Corp DE increased its position in Niagen Bioscience by 188.9% in the 1st quarter. Bank of America Corp DE now owns 304,718 shares of the company’s stock valued at $1,344,000 after acquiring an additional 199,227 shares in the last quarter. Finally, Quantinno Capital Management LP increased its position in Niagen Bioscience by 90.0% in the 1st quarter. Quantinno Capital Management LP now owns 50,946 shares of the company’s stock valued at $225,000 after acquiring an additional 24,135 shares in the last quarter. Institutional investors and hedge funds own 15.41% of the company’s stock.

Niagen Bioscience Stock Up 1.9%

NAGE opened at $3.17 on Friday. The stock’s 50 day moving average price is $3.26 and its two-hundred day moving average price is $3.95. The firm has a market capitalization of $252.46 million, a P/E ratio of 17.61 and a beta of 2.09. Niagen Bioscience has a 12-month low of $2.87 and a 12-month high of $10.52.

Niagen Bioscience (NASDAQ:NAGE) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.01. Niagen Bioscience had a net margin of 12.39% and a return on equity of 17.95%. The firm had revenue of $29.78 million during the quarter, compared to the consensus estimate of $29.95 million. As a group, analysts anticipate that Niagen Bioscience will post 0.13 earnings per share for the current year.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.